#1 Clinical Trials Search in Europe

Taldefgrobep Alfa

A clinical trial is underway to assess the effectiveness and safety of Taldefgrobep Alfa in patients with Spinal Muscular Atrophy (SMA). This study aims to explore the potential benefits of this drug as an additional therapy for individuals already receiving other SMA treatments. The trial focuses on both ambulatory and non-ambulatory participants, offering hope for improved motor function in people living with this neuromuscular condition.

Table of Contents

What is Taldefgrobep Alfa?

Taldefgrobep alfa, also known as BHV-2000 or BMS-986089, is a new drug being studied for the treatment of Spinal Muscular Atrophy (SMA) and other neuromuscular diseases[1]. It is designed to work alongside other SMA treatments to potentially improve muscle function and strength in patients.

Conditions Treated

The primary condition that taldefgrobep alfa aims to treat is Spinal Muscular Atrophy (SMA). SMA is a genetic disorder that affects the motor neurons, which are nerve cells in the spinal cord that control muscle movement. This condition leads to muscle weakness and wasting, making it difficult for patients to perform basic motor functions[1].

Additionally, the drug is being studied for its potential benefits in treating other neuromuscular diseases. These are a group of disorders that affect the muscles and their nervous system control[1].

How It Works

Taldefgrobep alfa works by targeting a protein called myostatin. Myostatin is a natural protein in the body that limits muscle growth and size. By blocking myostatin activity, taldefgrobep alfa aims to increase muscle size and improve muscle function[1].

This approach is different from other SMA treatments like nusinersen, risdiplam, or onasemnogene abeparvovec-xioi, which focus on increasing the amount of SMN protein (Survival Motor Neuron protein) in the body. The combination of taldefgrobep alfa with these SMN-enhancing medications has the potential to further improve motor function and clinical outcomes for people living with SMA[1].

Clinical Trial Details

A clinical trial is currently underway to evaluate the efficacy and safety of taldefgrobep alfa. Here are some key details about the study[1]:

  • Study Type: The trial is a randomized, double-blind, placebo-controlled study. This means that participants are randomly assigned to either receive taldefgrobep alfa or a placebo, and neither the participants nor the researchers know who is receiving which treatment during the study.
  • Participants: The study includes both ambulatory (able to walk) and non-ambulatory participants with Spinal Muscular Atrophy.
  • Duration: The study consists of a 48-week double-blind phase, followed by a 48-week open-label extension phase.
  • Adjunctive Therapy: Taldefgrobep alfa is being studied as an adjunctive therapy, meaning it’s used in addition to other SMA treatments. Participants in the study are already taking a stable dose of nusinersen or risdiplam, or have a history of treatment with onasemnogene abeparvovec-xioi.

Dosage and Administration

In the clinical trial, taldefgrobep alfa is administered as follows[1]:

  • Method of Administration: The drug is given as a subcutaneous injection (an injection under the skin).
  • Frequency: Injections are given weekly.
  • Dosage: The dose is weight-based, with participants receiving either 35 mg or 50 mg per injection.

Potential Benefits

The primary goal of the taldefgrobep alfa treatment is to improve motor function in people with SMA. The main outcome being measured in the clinical trial is the change in the 32-item Motor Function Measure (MFM-32) total score[1].

The MFM-32 is a scale used to assess motor function in patients with neuromuscular diseases. It consists of 32 items, each scored from 0 to 3, with higher scores indicating better motor function. By measuring the change in this score from the beginning to the end of the 48-week trial period, researchers hope to demonstrate that taldefgrobep alfa can significantly improve motor function in SMA patients[1].

If successful, taldefgrobep alfa could provide an additional treatment option for SMA patients, potentially enhancing the benefits of existing therapies and improving quality of life for those living with this challenging condition.

Aspect Details
Drug Name Taldefgrobep Alfa (also known as BHV-2000 or BMS-986089)
Condition Studied Spinal Muscular Atrophy (SMA)
Study Design Randomized, Double-Blind, Placebo-Controlled with Open-Label Extension
Duration 48-week Double-Blind phase + 48-week Open-Label Extension
Administration Weekly subcutaneous injection (35 mg or 50 mg, weight-based)
Mechanism of Action Blocks myostatin to potentially increase muscle size and function
Primary Outcome Measure Change in MFM-32 total score from baseline to Week 48
Participant Eligibility Ambulatory and non-ambulatory SMA patients on stable doses of nusinersen or risdiplam, or with history of onasemnogene abeparvovec-xioi treatment

FAQ

  • What is Taldefgrobep Alfa? Taldefgrobep Alfa is a drug that blocks myostatin, a protein that normally limits muscle growth. By inhibiting myostatin, Taldefgrobep Alfa has the potential to increase muscle size and function in patients with Spinal Muscular Atrophy.
  • How is Taldefgrobep Alfa administered in the trial? In the trial, Taldefgrobep Alfa is given as a weekly subcutaneous injection. The dose is weight-based, either 35 mg or 50 mg, depending on the participant's weight.
  • Who can participate in this clinical trial? The trial includes both ambulatory (able to walk) and non-ambulatory participants with Spinal Muscular Atrophy. Participants must already be taking a stable dose of nusinersen or risdiplam, or have a history of treatment with onasemnogene abeparvovec-xioi.
  • How long does the clinical trial last? The trial consists of a 48-week double-blind phase followed by a 48-week open-label extension phase, totaling 96 weeks (about 2 years) of treatment and observation.
  • How is the effectiveness of Taldefgrobep Alfa measured in this trial? The primary measure of effectiveness is the change in the 32-item Motor Function Measure (MFM-32) total score from the beginning of the trial to Week 48. This test assesses motor function, with higher scores indicating better functioning.

Ongoing Clinical Trials on Taldefgrobep Alfa

  • Study of Taldefgrobep Alfa for Patients with Spinal Muscular Atrophy on Stable Nusinersen and/or Risdiplam Regimen or with Onasemnogene Abeparvovec-xioi History

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Germany Italy The Netherlands Poland +1

Glossary

  • Spinal Muscular Atrophy (SMA): A genetic disorder characterized by weakness and wasting in muscles used for movement. It is caused by a loss of specialized nerve cells, called motor neurons, in the spinal cord and the part of the brain that is connected to the spinal cord.
  • Myostatin: A protein that acts as a negative regulator of muscle growth, meaning it limits muscle growth. Blocking myostatin can potentially increase muscle size and function.
  • Subcutaneous injection: A method of administering medication by injecting it into the tissue layer between the skin and the muscle.
  • Double-blind study: A type of clinical trial where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo. This helps prevent bias in the study results.
  • Placebo: A substance that has no therapeutic effect, used as a control in testing new drugs. In this study, some participants receive a placebo that looks like the real medication but contains no active ingredients.
  • Open-label extension: A phase of a clinical trial where all participants receive the active treatment, and both researchers and participants know what is being administered.
  • Motor Function Measure (MFM-32): A scale used to assess motor function in patients with neuromuscular diseases. It consists of 32 items, each scored from 0 to 3, with higher scores indicating better motor function.
  • Nusinersen: An approved medication for treating SMA that works by increasing the production of the survival motor neuron (SMN) protein.
  • Risdiplam: Another approved medication for SMA that also increases the production of the SMN protein.
  • Onasemnogene abeparvovec-xioi: A gene therapy treatment for SMA that provides a functional copy of the SMN1 gene to motor neurons.

References